Live

reimbursement

2 articles

Natera Positioned to Capture $20B MRD Market as Testing Adoption Accelerates

Benzinga

Benzinga·Apr 14·Vandana Singh

Natera Positioned to Capture $20B MRD Market as Testing Adoption Accelerates

William Blair initiates Natera coverage, citing $1B MRD revenue in 2025 with 40%+ growth expected in 2026 as penetration rises.

NTRAmarket opportunitycompetitive advantage

DexCom Positioned as Hidden Beneficiary in GLP-1 Drug Expansion

The Motley Fool

The Motley Fool·Feb 25·Prosper Junior Bakiny

DexCom Positioned as Hidden Beneficiary in GLP-1 Drug Expansion

DexCom benefits from GLP-1 drug expansion as CGM devices are increasingly prescribed together, unlocking significant untapped patient markets and complementary revenue opportunities.

DXCMhealthcare stocksmedical devices